Active, not recruitingNCT05424562
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Enrollment
- 210 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (20)
- Tom Baker Cancer Centre /ID# 248113, Calgary, Alberta, Canada
- University of Alberta Hospital /ID# 251531, Edmonton, Alberta, Canada
- BC Cancer - Surrey /ID# 257515, Surrey, British Columbia, Canada
- Vancouver General Hospital /ID# 245438, Vancouver, British Columbia, Canada
- BC Cancer - Victoria /ID# 257339, Victoria, British Columbia, Canada
- CancerCare Manitoba /ID# 246414, Winnipeg, Manitoba, Canada
- The Moncton Hospital /ID# 247277, Moncton, New Brunswick, Canada
- Eastern Regional Health Authority /ID# 250241, St. John's, Newfoundland and Labrador, Canada
- Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 246514, Halifax, Nova Scotia, Canada
- Juravinski Cancer Centre /ID# 247183, Hamilton, Ontario, Canada
- Kingston Health Sciences Centre /ID# 253439, Kingston, Ontario, Canada
- London Health Sciences Center- University Hospital /ID# 248027, London, Ontario, Canada
- Lakeridge Health - Oshawa /ID# 246412, Oshawa, Ontario, Canada
- Thunder Bay Regional Research Institute /ID# 249163, Thunder Bay, Ontario, Canada
- Sunnybrook Health Sciences Centre /ID# 251966, Toronto, Ontario, Canada
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05424562 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital